Patrik Nordenfelt

TL;DR: Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches.

TL;DR: There is a paucity of double-blind, placebo-controlled trials on the treatment of HAE, making levels of evidence to support the algorithm less than optimal.

TL;DR: Hereditary angioedema due to C1 inhibitor deficiency is a rare disease characterized by attacks of edema, known to impact quality of life (QoL) and the burden of HAE in Swedish patients, both children and adults is investigated.

TL;DR: An international multidisciplinary group of 14 experts in HAE genetics and disease management was convened in October 2018 to develop clear, actionable, evidence- and consensus-based statements aiming to facilitate the communication between physicians treating HAE patients and clinical geneticists, and thus promote the effective use of genetics in the management of the disease.

TL;DR: Pain, anxiety/depression, and fatigue/mood are important aspects of HAE but the AE-QoL disregards pain, which justifies more active disease management.